CLINICAL TRIALS PROFILE FOR GEPIRONE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for gepirone hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000189 ↗ | Gepirone vs Placebo in Treatment of Cocaine Dependence - 3 | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 1990-01-01 | The purpose of this study is to test antidepressant medication, gepirone, as a pharmacotherapy for cocaine dependent subjects. |
| NCT00000189 ↗ | Gepirone vs Placebo in Treatment of Cocaine Dependence - 3 | Completed | University of Pennsylvania | Phase 2 | 1990-01-01 | The purpose of this study is to test antidepressant medication, gepirone, as a pharmacotherapy for cocaine dependent subjects. |
| NCT00610506 ↗ | Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features | Completed | Forest Laboratories | Phase 3 | 2005-10-01 | Aims of Study: The aims of this study are 1) to examine the clinical utility of escitalopram in patients with major depression with atypical features; 2) to evaluate the tolerability of escitalopram in major depression with atypical features. Study hypothesis and objectives. This study is proposed as an open-label study to gather pilot data to examine whether escitalopram has clinical utility in the treatment of major depression with atypical features. Because of the exploratory nature of the design, no specific study hypotheses can be generated regarding efficacy of the drug. Our primary hypothesis is that the effect size of escitalopram in atypical depression will be similar to the effect size of escitalopram in major depression, its FDA approved indication. |
| NCT00610506 ↗ | Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features | Completed | Duke University | Phase 3 | 2005-10-01 | Aims of Study: The aims of this study are 1) to examine the clinical utility of escitalopram in patients with major depression with atypical features; 2) to evaluate the tolerability of escitalopram in major depression with atypical features. Study hypothesis and objectives. This study is proposed as an open-label study to gather pilot data to examine whether escitalopram has clinical utility in the treatment of major depression with atypical features. Because of the exploratory nature of the design, no specific study hypotheses can be generated regarding efficacy of the drug. Our primary hypothesis is that the effect size of escitalopram in atypical depression will be similar to the effect size of escitalopram in major depression, its FDA approved indication. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for gepirone hydrochloride
Condition Name
Clinical Trial Locations for gepirone hydrochloride
Trials by Country
Clinical Trial Progress for gepirone hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for gepirone hydrochloride
Sponsor Name
